Head and Neck Cancer Therapeutics Market to Surpass USD 2934.26 Million by 2026
Increasing cases of head and neck cancer
and spike in demand for combination therapy is expected to drive global head
and neck cancer therapeutics market.
According to TechSci Research report, “Global Head and Neck Cancer Therapeutics Market By Diagnostic
Methods (Biopsy, Imaging, Endoscopy, Others), By Treatment Type (Surgery,
Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), By Disease
Indication (Lip and Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer,
Salivary Gland Cancer, Nasopharyngeal
Cancer, Hypopharyngeal Cancer), By Route of Administration (Injectable, Oral),
By Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors),
By End User (Hospitals, Specialty
Clinics, Ambulatory Surgical Centres, Others), By Region, Forecast &
Opportunities, 2026”, the market is anticipated
to witness a robust CAGR of 7.71% during the forecast period. The growth in
global head and neck cancer therapeutics market can be attributed to rising
prevalence of head and neck cancer around the world and growing geriatric
population, which is more vulnerable to cancer. At present, more than 43
products are undergoing clinical trials for the head and neck cancer
therapeutics market. In some cases, early diagnosed cancers are curable but the
treatment varies on the basis of extent, location and type of the disease.
Latest advances in surgical techniques and nonsurgical therapies such as targeted
therapy and immunotherapy aid in preserving the quality of life while offering
the most effective care. Apart from this, technological advancements in the
screening procedure for cancer and various pipeline drugs such as Atezolizumab,
Erlotinib, Ipilimumab, Durvalumab, Avelumab, Afatinib, Bevacizumab, and others will
have a positive impact on the market which will further drive the market growth.
Moreover,
governments and private organizations’ initiative to provide improved
healthcare service and beneficial healthcare reforms are supporting the growth
of the global head and neck cancer therapeutics market. Also, growing
popularity of immunotherapy for head and neck cancer treatment is expected to
provide huge growth opportunities for pharmaceutical companies. Furthermore,
cancer awareness programs and early cancer diagnosis are acting as some other
key growth drivers for head and neck cancer therapeutics market.
Browse and 190 Figures
spread through 110 Pages and an in-depth TOC on "Global
Head and Neck Cancer Therapeutics Market"
https://www.techsciresearch.com/report/head-and-neck-cancer-therapeutics-market/5056.html
The global head and neck cancer therapeutics market
is segmented based on diagnostic methods, treatment type, disease indication,
route of administration, therapeutic class, end user and region. Based on
disease indication, the market can be segmented into laryngeal cancer, lip and
oral cavity cancer, nasopharyngeal cancer, oropharyngeal cancer, salivary gland
cancer and others. Among them, lip and oral cavity cancer is expected to
contribute largest share through 2026 due to a large patient pool affected by
lip and oral cancer globally.
Based on therapeutic class, global head and neck
cancer therapeutics market can be segmented into PD inhibitors, microtubule
inhibitors and EGFR inhibitors. Among them, PD inhibitor drug class is expected
to grow significantly during the forecast period owing to new product launches.
Major players operating in the global head and neck
cancer therapeutics market include AstraZeneca Plc.,
Astellas Pharma Inc., AB Science SA, Bristol-Myers Squibb Company, Boston
Biomedical, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd. (Genentech,
Inc.,), Fresenius Medical Care AG & Co. KGaA, Sun Pharmaceutical Industries
Ltd., Teva Pharmaceutical Industries Limited, Merck & Co., Inc., Pfizer
Inc., Sanofi S.A., Bayer AG and AbbVie Inc. The players are undergoing
extensive R&D activities to develop new therapeutic drugs and increase
their global market share.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=5056
Customers can also request for 10% free
customization on this report.
“North
America is expected to contribute to the largest share in the global head and
neck cancer therapeutics market as United States is witnessing high prevalence
HPV-induced cancers. However, Asia Pacific is expected to register fastest CAGR
during the forecast period owing to rising incidences of head & neck cancer.
The risk factors such as increase in cigarette smoking and usage of tobacco is
also making the region a lucrative market for drug manufacturing companies,” said
Mr. Karan Chechi, Research Director with TechSci Research, a research based
global management consulting firm.
“Global
Head and Neck Cancer Therapeutics Market By Diagnostic Methods (Biopsy,
Imaging, Endoscopy, Others), By Treatment Type (Surgery, Radiation Therapy, Chemotherapy,
Immunotherapy, Targeted Therapy), By Disease Indication (Lip and Oral Cavity
Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer),
By Route of Administration (Injectable, Oral), By Therapeutic Class (PD
Inhibitors, EGFR Inhibitors, Microtubule Inhibitors), By End User (Hospitals, Specialty Clinics,
Ambulatory Surgical Centres, Others), By Region, Forecast & Opportunities,
2026” has
evaluated the future growth potential of global head and neck cancer
therapeutics market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges and opportunities in the global head and neck
cancer therapeutics market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com/